Navigation Links
Raptor Pharmaceuticals Closes $10 Million Private Placement
Date:6/30/2008

reseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including our Registration Statement on Form SB-2, as amended, that was declared effective on July 10, 2006; our annual report on Form 10-KSB filed with the SEC on November 14, 2007; and our Form 10-QSB filed with the SEC on April 15, 2008, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our reports filed with the SEC. We expressly disclaim any intent or obligation to update any forward-looking statements.

For more information, please contact:

The Ruth Group

Sara Ephraim (investors) Janine McCargo (media)

(646) 536-7002 (646) 536-7033

sephraim@theruthgroup.com jmccargo@theruthgroup.com


'/>"/>
SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
4. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
5. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... -- Investor-Edge has initiated coverage on ... GENE ), Agilent Technologies Inc. (NYSE: A ... ), Sequenom Inc. (NASDAQ: SQNM ), and ... report on Genetic Technologies can be accessed at ... the NASDAQ Composite ended at 4,941.42, down 1.64%, ...
(Date:5/1/2015)... SPRING, Md. and RESEARCH TRIANGLE PARK, ... (NASDAQ: UTHR ) announced today that Roger Jeffs ... will provide an overview and update on the company,s business ... Conference in Boston, Massachusetts . ... at 3:30 PM Eastern Time, and can be accessed via ...
(Date:4/30/2015)... 2015   Tamir Biotechnology , a leading developer ... its Ebola antiviral therapy program. Clinical ... currently being evaluated and considered by a number of ... During the first quarter of 2015, the company participated ... The Evaluation of Potential Treatments and Vaccines For Ebola ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... any tissue with the Big Blue transgenic,rodent ... Barry W. Glickman ,Centre for Environmental Health, University of ... transgenic rodent mutation,assay,* which carries the ... vector, it is easy to study mutations in male,and ...
... and efficient PCR cloning with pcmv-script PCR cloning kit ... Tim Sanchez Quinn,Lu ,Stratagene Cloning Systems, Inc. , ... cloning,strategy by introducing a new vector for ... The pcmv-script PCR,cloning kit ...
... reagent is effective with a wide variety ... ,Genetic Applications LLC , LipoTAXI ... delivery of foreign DNA into mammalian,cells. In this study, ... conditions for transfecting a reporter plasmid in three common ...
Cached Biology Technology:Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 2Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 3Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 4Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 5Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 6Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 7Mammalian Expression Vector for Efficient Cloning of PCR Fragments 2Mammalian Expression Vector for Efficient Cloning of PCR Fragments 3Mammalian Expression Vector for Efficient Cloning of PCR Fragments 4A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7,Cell Lines 2A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7,Cell Lines 3
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... French . Toronto (June 5, 2009) ... to announce another measure to address the H1N1 flu virus. ... network focused on pandemic vaccine evaluation. The network will strengthen ... pandemic influenza vaccine and vaccination programs. The network was ...
... may shape the human genome much more slowly than ... within and among continents, the expansions and contractions of ... heavily influenced the distribution of genetic variations in populations ... from the Howard Hughes Medical Institute, the University of ...
... EAST LANSING, Mich. A pair of Michigan ... $400,000 for their cardiovascular research projects as part of ... The money, from the National Institutes of Health ... to preserve and create jobs in Michigan while also ...
Cached Biology News:Government of Canada announces funding for research on the H1N1 flu virus 2Geography and history shape genetic differences in humans 2MSU researchers receive $400,000 in first wave of stimulus funding 2
Porcine Serum US Origin 6 Months or Older...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
... off the clot from fasted Cynomolgus monkeys of mixed ... Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) N-03: ... CPD N-09: K3EDTA N-11: Heparin ...
adult...
Biology Products: